TW202405018A - Cd73抗體雞尾酒療法 - Google Patents

Cd73抗體雞尾酒療法 Download PDF

Info

Publication number
TW202405018A
TW202405018A TW112121274A TW112121274A TW202405018A TW 202405018 A TW202405018 A TW 202405018A TW 112121274 A TW112121274 A TW 112121274A TW 112121274 A TW112121274 A TW 112121274A TW 202405018 A TW202405018 A TW 202405018A
Authority
TW
Taiwan
Prior art keywords
antigen
binding protein
pharmaceutical composition
seq
acid sequence
Prior art date
Application number
TW112121274A
Other languages
English (en)
Chinese (zh)
Inventor
徐錦根
賈慧峰
一帆 占
潘現飛
于海佳
王少杰
夏思敏
向陽 朱
Original Assignee
大陸商上海華奧泰生物藥業股份有限公司
大陸商華博生物醫藥技術(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海華奧泰生物藥業股份有限公司, 大陸商華博生物醫藥技術(上海)有限公司 filed Critical 大陸商上海華奧泰生物藥業股份有限公司
Publication of TW202405018A publication Critical patent/TW202405018A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW112121274A 2022-06-08 2023-06-07 Cd73抗體雞尾酒療法 TW202405018A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022106393314 2022-06-08
CN202210639331 2022-06-08

Publications (1)

Publication Number Publication Date
TW202405018A true TW202405018A (zh) 2024-02-01

Family

ID=89117604

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112121274A TW202405018A (zh) 2022-06-08 2023-06-07 Cd73抗體雞尾酒療法

Country Status (8)

Country Link
US (1) US20260217849A1 (cg-RX-API-DMAC10.html)
EP (1) EP4538289A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025521231A (cg-RX-API-DMAC10.html)
KR (1) KR20250023471A (cg-RX-API-DMAC10.html)
CN (1) CN119403832A (cg-RX-API-DMAC10.html)
CA (1) CA3258260A1 (cg-RX-API-DMAC10.html)
TW (1) TW202405018A (cg-RX-API-DMAC10.html)
WO (1) WO2023236971A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
AU2017228470A1 (en) * 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
EP4058150A2 (en) * 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗cd73抗体及びその使用
TWI900705B (zh) * 2020-12-11 2025-10-11 大陸商上海華奧泰生物藥業股份有限公司 Cd73的抗原結合蛋白及其應用
US20240067747A1 (en) * 2021-01-13 2024-02-29 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd73-binding protein and use thereof

Also Published As

Publication number Publication date
JP2025521231A (ja) 2025-07-08
US20260217849A1 (en) 2026-07-30
CA3258260A1 (en) 2025-03-18
WO2023236971A1 (zh) 2023-12-14
EP4538289A1 (en) 2025-04-16
EP4538289A4 (en) 2026-06-17
KR20250023471A (ko) 2025-02-18
CN119403832A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
JP2023036900A (ja) 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法
KR101782203B1 (ko) 동결건조 및 수성 항-cd40 항체 제제
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
TW200944245A (en) Powdered protein compositions and methods of making same
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2022521624A (ja) 抗cd47抗体を含む製剤、その調製方法および使用
TW201825122A (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
TWI860741B (zh) Pvrig/tigit雙特異性抗體藥物組合物及其用途
TWI484975B (zh) 以抗介白素-20抗體治療口腔癌之醫藥組成物
TWI782397B (zh) 重組全人源抗tigit單株抗體製劑及其製備方法和用途
CA3064470A1 (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
JP2025528019A (ja) Il-2プロサイトカイン抗体融合タンパク質
KR20210153039A (ko) 커넥신 43 항체 및 이의 용도
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
US20240182537A1 (en) Il-15 procytokine antibody fusion proteins
KR20210097750A (ko) Cd40 항체 약학 조성물 및 이의 용도
WO2023236971A1 (zh) Cd73抗体鸡尾酒疗法
CN114007648B (zh) 包含抗lag-3抗体的制剂、其制备方法及其用途
CN118576543A (zh) 一种结合人CD3/IL13Rα的双特异性抗体制剂及其应用
JP2022176154A (ja) ムコ多糖症i型の治療用医薬組成物
CN112675300A (zh) 包含抗gitr抗体的制剂及其制备方法和用途
EA053234B1 (ru) Терапия коктейлем антител против cd73
EP4501313A1 (en) Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof
US20240092914A1 (en) Depletion and inhibition of plasmacytoid dendritic cells
CN114316046B (zh) 一种稳定的抗体组合物